On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]
Referencesedit
^Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, et al. (February 2008). "Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders". Neuropsychopharmacology. 33 (3): 574–87. doi:10.1038/sj.npp.1301424. PMID 17460614.
^Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression". Pharmacology, Biochemistry, and Behavior. 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519. S2CID 35026036.
^Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.
This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.
amibegron, 611a, drug, developed, sanofi, aventis, sanofi, which, acts, selective, agonist, adrenergic, receptor, first, orally, active, agonist, developed, that, capable, entering, central, nervous, system, antidepressant, anxiolytic, effects, clinical, datar. Amibegron SR 58 611A was a drug developed by Sanofi Aventis now Sanofi which acts as a selective agonist for the b3 adrenergic receptor It is the first orally active b3 agonist developed that is capable of entering the central nervous system and has antidepressant and anxiolytic effects 1 2 AmibegronClinical dataRoutes ofadministrationOralATC codenoneLegal statusLegal statusDevelopment terminatedIdentifiersIUPAC name Ethyl 7S 7 2R 2 3 chlorophenyl 2 hydroxyethyl amino 5 6 7 8 tetrahydronaphthalen 2 yl oxy acetateCAS Number121524 08 1 YHCl 121524 09 2 YPubChem CID3035442IUPHAR BPS568ChemSpider108738 YUNIIPDQ3ME68U3HCl N910CJ679E YKEGGD08851 YChEMBLChEMBL545437 YCompTox Dashboard EPA DTXSID6047361Chemical and physical dataFormulaC 22H 26Cl N O 4Molar mass403 90 g mol 13D model JSmol Interactive imageSMILES CCOC O COc3ccc1CCC Cc1c3 NCC O c2cc Cl ccc2InChI InChI 1S C22H26ClNO4 ClH c1 2 27 22 26 14 28 20 9 7 15 6 8 19 11 17 15 12 20 24 13 21 25 16 4 3 5 18 23 10 16 h3 5 7 9 10 12 19 21 24 25H 2 6 8 11 13 14H2 1H3 1H t19 21 m0 s1 YKey NQIZCDQCNYCVAS RQBPZYBGSA N Y verify On July 31 2008 Sanofi Aventis announced that it has decided to discontinue development of amibegron 3 References edit Stemmelin J Cohen C Terranova JP Lopez Grancha M Pichat P Bergis O et al February 2008 Stimulation of the beta3 Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders Neuropsychopharmacology 33 3 574 87 doi 10 1038 sj npp 1301424 PMID 17460614 Overstreet DH Stemmelin J Griebel G June 2008 Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression Pharmacology Biochemistry and Behavior 89 4 623 6 doi 10 1016 j pbb 2008 02 020 PMID 18358519 S2CID 35026036 Second quarter 2008 results July 31 2008 retrieved March 9 2009 nbsp This article about an anxiolytic is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Amibegron amp oldid 1081388708, wikipedia, wiki, book, books, library,
